NEWS

November 17, 2017

Acorda Announces Royalty Monetization Transactions for $53 Million

October 26, 2017

FDA Recognizes Orphan Drug Exclusivity for Adamas’ GOCOVRI™

October 1, 2017

Profiles in Leadership – Robert Langer: From an Ugly Duckling to Singular Swan

September 29, 2017

HealthCare Royalty Partners expands U.K. operations

August 24, 2017

Adamas Announces FDA Approval of GOCOVRI™ as First and Only Medication for the Treatment of Dyskinesia in Parkinson’s Disease Patients

August 15, 2017

Portola Pharmaceuticals Announces AndexXa® (Andexanet Alfa) Biologics License Application Resubmission Accepted for Review by U.S. FDA

August 4, 2017

Johnson & Johnson Vision Announces Agreement to Acquire TearScience

May 18, 2017

Shire’s Investigational Treatment Lanadelumab Reduces Hereditary Angioedema Monthly Attack Rate by 87% Versus Placebo in Phase 3 26-week Pivotal Trial

May 16, 2017

Coherus BioSciences Prevails in ‘135 IPR Decision

May 11, 2017

Adamas Signs $100 Million Royalty-Backed Note Agreement with HealthCare Royalty Partners